Stock Scorecard
Stock Summary for Apellis Pharmaceuticals Inc (APLS) - $47.93 as of 4/26/2024 12:34:28 PM EST
Total Score
6 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for APLS
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for APLS
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for APLS
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for APLS
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for APLS
Financial Details for APLS
Company Overview |
|
|---|---|
| Ticker | APLS |
| Company Name | Apellis Pharmaceuticals Inc |
| Country | USA |
| Description | Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 5/2/2024 |
Stock Price History |
|
| Last Day Price | 47.93 |
| Last Day Price Updated | 4/26/2024 12:34:28 PM EST |
| Last Day Volume | 1,122,466 |
| Average Daily Volume | 1,182,816 |
| 52-Week High | 94.75 |
| 52-Week Low | 19.83 |
| Last Price to 52 Week Low | 141.70% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 101.20 |
| Sector PE | 61.73 |
| 5-Year Average PE | -7.84 |
| Free Cash Flow Ratio | 16.47 |
| Industry Free Cash Flow Ratio | 12.66 |
| Sector Free Cash Flow Ratio | 30.74 |
| Current Ratio Most Recent Quarter | 3.10 |
| Total Cash Per Share | 2.91 |
| Book Value Per Share Most Recent Quarter | 1.63 |
| Price to Book Ratio | 32.10 |
| Industry Price to Book Ratio | 5.66 |
| Sector Price to Book Ratio | 22.08 |
| Price to Sales Ratio Twelve Trailing Months | 15.75 |
| Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
| Sector Price to Sales Ratio Twelve Trailing Months | 5.16 |
Share Statistics |
|
| Total Shares Outstanding | 120,582,000 |
| Market Capitalization | 5,779,495,260 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 18.94% |
| Reported EPS 12 Trailing Months | -4.45 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | -4.48 |
| Net Income Twelve Trailing Months | -528,628,000 |
| Net Income Past Year | -528,628,000 |
| Net Income Prior Year | -652,172,000 |
| Quarterly Revenue Growth YOY | 546.00% |
| 5-Year Revenue Growth | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 351,185,000 |
| Total Cash Past Year | 351,185,000 |
| Total Cash Prior Year | 551,800,000 |
| Net Cash Position Most Recent Quarter | 258,152,000 |
| Net Cash Position Past Year | 258,152,000 |
| Long Term Debt Past Year | 93,033,000 |
| Long Term Debt Prior Year | 92,736,000 |
| Total Debt Most Recent Quarter | 93,033,000 |
| Equity to Debt Ratio Past Year | 0.68 |
| Equity to Debt Ratio Most Recent Quarter | 0.68 |
| Total Stockholder Equity Past Year | 194,521,000 |
| Total Stockholder Equity Prior Year | 169,872,000 |
| Total Stockholder Equity Most Recent Quarter | 194,521,000 |
Options |
|
| Put/Call Ratio | 0.64 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -2.90 |
| MACD Signal | -2.66 |
| 20-Day Bollinger Lower Band | 46.69 |
| 20-Day Bollinger Middle Band | 59.80 |
| 20-Day Bollinger Upper Band | 72.90 |
| Beta | 0.89 |
| RSI | 36.18 |
| 50-Day SMA | 58.02 |
| 200-Day SMA | 51.25 |
System |
|
| Modified | 4/24/2024 5:41:58 PM EST |